

Ventricular Repolarization in Diabetic Patients: Characterization and Clinical Implications

David Clemente¹, Telmo Pereira^{2,4}, Susana Ribeiro³

Unidade de Cuidados de Saúde Personalizados de Salvaterra de Magos¹; Escola Superior de Tecnologia da Saúde de Coimbra²; Unidade de Saúde Familiar de Samora Correia³, Santarém - Portugal, Universidade Metodista de Angola⁴ - África

Abstract

Background: Diabetes *mellitus* is a chronic and very common condition, and there has been lately a considerable increase in its prevalence and incidence. Diabetic patients have increased cardiovascular mortality, in which malignant ventricular arrhythmias seem to be implicated.

Objective: To study the effects of diabetes on ventricular repolarization parameters responsible for an increased susceptibility to malignant ventricular arrhythmias and/or sudden death.

Methods: We selected a group of 110 diabetic patients and a group of 110 controls with the same distribution of age, gender and race. We evaluated the following parameters of ventricular repolarization: QT_{max}' , QT_{mean}' , QT_{min}' , QTc_{max}' , QTc_{mean}' , QTc_{min}' , QT and QTc dispersions, $T_{peak}-T_{end}$ and $jT_{peak}-jT_{end}$ intervals (D_{II}' , V_2 and V_5), $T_{peak}-T_{end}$ and $jT_{peak}-jT_{end}$ dispersions. The electrocardiograms (ECG) were performed by the same operator and reviewed by the same observers. QT intervals were corrected according to Bazett's formula.

Results: We found significantly higher values of QTc_{max} ($p < 0.001$), QTc_{mean} ($p < 0.001$), QT dispersion ($p < 0.001$), QTc dispersion ($p < 0.001$), $T_{peak}-T_{end}$ dispersion ($p < 0.001$), and $jT_{peak}-jT_{end}$ dispersion ($p < 0.001$) in diabetic patients than in controls. In diabetic patients, we observed prolonged values of QTc interval (5.5%), QT dispersion (0.9%), QTc dispersion (0%), $T_{peak}-T_{end}$ interval (7.3%), $jT_{peak}-jT_{end}$ interval (6.4%), $T_{peak}-T_{end}$ dispersion (16.4%), and $jT_{peak}-jT_{end}$ dispersion (12.7%). In the controls there were no prolonged values of any of the parameters.

Conclusion: We concluded that diabetes causes prolongation and spatial dispersion of repolarization, and it may contribute to a greater ventricular electrical instability, whose expected clinical expression may be malignant ventricular arrhythmias. (Arq Bras Cardiol 2012;99(5):1015-1022)

Keywords: Arrhythmias cardiac; diabetes mellitus; electrocardiography; death; sudden; cardiac.

Introduction

Diabetes mellitus is one of the most common chronic diseases in the world affecting about 6.4% of the world population. Its prevalence continues to increase exponentially, and it is estimated that in 2030 it will reach 7.7% of the adult population¹. Patients with diabetes mellitus have high cardiovascular morbidity and mortality. This risk remains elevated even after normalization of conventional cardiovascular risk factors (hypertension, dyslipidemia, physical inactivity, smoking habit, etc.), which suggests the existence of other mechanisms. The ventricular electrical instability, manifested in changes in the QT interval, appears to be another important mechanism².

Diabetes is associated with greater prolongation and spatial dispersion of repolarization that lead to greater

regional heterogeneity of repolarization due to differences in the duration of the action potential, providing the substrate for malignant ventricular arrhythmias, which may result in sudden death³⁻⁵.

For the identification of individuals at high risk, several markers for arrhythmogenic risk have been identified using the ventricular repolarization parameters of a simple 12-lead electrocardiogram. Some of these markers have already been well established in several studies; however, there are others that require further investigation⁶.

The main objective of this study was to evaluate the effect of diabetes on the ventricular repolarization parameters responsible for an increased susceptibility to malignant ventricular arrhythmias and/or sudden death. We conducted a comparative analysis, between diabetic patients and controls, of the following parameters: QT and QTc intervals, QT and QTc dispersions, $T_{peak}-T_{end}$ and $jT_{peak}-jT_{end}$ intervals, and $T_{peak}-T_{end}$ and $jT_{peak}-jT_{end}$ dispersions. Finally, we performed a correlation analysis between some variables and the aforementioned repolarization parameters.

Mailing Address: David da Silva Clemente •

Urbanização das Milheiras - Rua C, Lote 110 R/C Distrito de Santarém.

Postal Code 2080-001, Santarém, Portugal

E-mail: david_s_clemente@hotmail.com

Manuscript received January 13, 2012; manuscript revised March 21, 2012; accepted July 31, 2012.

Methods

Sample

We conducted a cross-sectional study based on a sample of 220 individuals, of whom 110 were diabetic and 110 healthy individuals (by clinical and laboratory evaluation) selected for pairing. Of the 110 individuals with the disease, 106 had type 2 diabetes, and 4 had type 1 diabetes.

Data collection was performed at the Department of Cardiology of the Personalized Healthcare Units (UCSP) of Salvaterra de Magos and of Marinhais, in Portugal.

Inclusion criteria encompassed all individuals diagnosed with diabetes mellitus; however, we excluded all patients with chronic atrial fibrillation, atrial flutter, left/right bundle branch block, pre-excitation syndromes, patients with pacemakers, drug addicts, and dialysis patients. We also excluded patients treated with drugs that prolong the QT interval, as suggested by the European Society of Cardiology (ESC)⁷.

The study is in compliance with the Declaration of Helsinki and was approved by the ethics committees of all UCSPs involved. All study subjects signed an informed consent form.

Procedure

To obtain the sample, we initially accessed the list of diabetic patients enrolled in Salvaterra de Magos, and the exclusion criteria were established.

We conducted a simple 12-lead ECG in all diabetic patients. The ECG was always performed with the patient supine, at rest, at a paper speed of 50 mm/s and voltage of 10 mm/mV. To make the ECGs we used the electrocardiograph Cardioline-Delta 1 Plus[®], in the UCSP of Salvaterra de Magos, and the electrocardiograph Nihon Kohden Ecaps 12-ECG 8119K[®], in the UCSP of Marinhais. For the control group we also conducted simple 12-lead electrocardiograms under the same conditions and measurements used for the diabetic patients. The control subjects were required to have a normal ECG and to be healthy in the clinical assessment and the physical examination, with no pathologic processes that might affect ventricular repolarization. To this end, we conducted a consultation of the clinical process and only one ECG of the individuals that met the desired criteria. The control group was selected by pairing, allowing an adjustment of the two groups for age, gender, and ethnicity.

For the analysis of the ECG, we performed a manual measurement of the values using a digital caliper with measuring range of 0-150 mm, 0.01 mm resolution, and 0-100 ± 0.02 mm accuracy. The value obtained was converted to milliseconds (ms). We considered the T-wave peak as the steepest point, and the T-wave end as the point of return to the baseline. The T-wave end was obtained by the intersection point of the tangent line of the terminal portion of the T-wave with the isoelectric line. When the U-wave was present, the T-wave end was considered as the nadir between the T-wave and the U-wave. The derivations in which it was not possible to define the T-wave end due to low voltage were discarded.

Measurement of the QT interval (the interval from the start of the QRS complex to the end of the T-wave) was performed

in all 12 leads, and the longest and the shortest intervals measured were selected. QT interval dispersion was obtained by the difference between the maximum and the minimum QT intervals found in the 12-lead electrocardiogram.

Measurement of the QT_{peak} (the interval from the start of the QRS complex to the peak of the T-wave) was conducted in D_{II}, V₂, and V₅ leads. Measurement of the QT_{end} (the interval from the start of the QRS complex to the end of the T-wave) was also conducted in D_{II}, V₂, and V₅ leads. The T_{peak}-T_{end} interval was obtained by the difference between the QT_{end} and the QT_{peak}.

The QT interval was also corrected according to Bazett's formula which consists in dividing the measured QT by the square root of the RR interval (QTc = QT/√RR), thus providing the QT interval value adjusted for heart rate.

The QTc dispersion was obtained by the difference between the highest and the lowest values of QTc in the 12 leads of the ECG.

According to internationally accepted guidelines, the QTc interval was considered prolonged when higher than 440 ms for male patients, and higher than 460 ms for female patients⁸. The QT dispersion was considered prolonged when higher than 65 ms, according to other previously conducted studies^{9,10}.

Measurement of the jT_{peak} (the interval from J point to the peak of the T-wave) was conducted in D_{II}, V₂, and V₅ leads. Measurement of the jT_{end} (the interval from the start of the QRS complex to the end of the T-wave) was also conducted in D_{II}, V₂, and V₅ leads. The jT_{peak}-jT_{end} interval was obtained by the difference between the jT_{end} and the jT_{peak}.

The T_{peak}-T_{end} interval dispersion was obtained by the difference between the largest and the smallest intervals in D_{II}, V₂ and V₅ leads.

The Tpeak-Tend interval was considered prolonged when greater than 100 ms, and the Tpeak-Tend dispersion was considered prolonged when higher than 20 ms, as suggested by other studies^{11,12}.

The ECG was performed by the same operator, and the aforementioned measurements were made by two independent observers. In case of disagreement on the values obtained, the measurements were repeated by a third observer with expertise in electrocardiographic analysis.

The body mass index (BMI) was divided into several classes as proposed by the World Health Organization (WHO)¹³. Hypertension was divided into several classes according to the recommendations of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)¹⁴. Reference values for biochemical parameters used in this study were those recommended by the Massachusetts General Hospital¹⁵.

Statistical Analysis

The collected data were entered in the software SPSS for Windows, version 18.0, which performed a statistical analysis.

The distribution of variables was tested for normality using the Kolmogorov-Smirnov test, and the heterogeneity of variances was evaluated by Levene's test. A simple descriptive analysis was performed for the general characterization of the sample and distribution of variables.

Differences between groups were analyzed using the Student t test for independent samples. Categorical data were analyzed using the chi-square (X^2) test. The correlations between variables were analyzed using Pearson's correlation coefficient (r).

Continuous variables were presented as mean \pm standard deviation, and categorical variables were presented as frequency (%).

A p value < 0.05 was considered statistically significant for a confidence interval of 95%.

Results

Sample Characterization

The sample used for this study involved the same number of diabetic patients ($n = 110$) and controls ($n = 110$). All individuals in the sample were Caucasian. In both groups there was a slight predominance of males, but no statistically significant differences ($p = 0.063$) were observed. The proportion of men in both groups was 54.5%, and 45.5% for women. As expected, there were no statistically significant differences in age between the diabetic group and the control group (mean age 67.35 ± 9.20 years versus 65.99 ± 8.99 years, respectively, $p = 0.260$).

The diabetic group had a mean BMI significantly higher than the control group (28.38 ± 3.69 kg/m² versus 26.77 ± 3.13 kg/m², $p = 0.001$). In both cases, the average BMI was above the upper limit of normality suggested by WHO. BMI values classified according to the degree of obesity were compared between diabetic patients and controls. The results showed that a high percentage of diabetic patients and controls had pre-obesity (47.3% and 60.7% respectively), with a reduction in the proportion of individuals as the BMI increased in both groups. In the three degrees of obesity, there was always a higher percentage of diabetic patients, and in underweight, normal weight and pre-obesity categories, there were greater proportions of controls. The differences in the distribution of individuals in each group by BMI classes were significant, and in the diabetic group there was a greater relative proportion of patients with weight above the upper limit of normal.

Regarding the type of diabetes identified in patients included in the diabetic group, most had type 2 diabetes (96.4%), and the others had type 1 diabetes (3.6%). The mean age at diagnosis was 55.10 ± 12.38 years, and currently the mean duration of the disease is 12.25 ± 9.59 years.

With regard to blood pressure values, the diabetic group had an average systolic blood pressure of 141.76 ± 14.11 mmHg,

and a mean diastolic blood pressure of 78.05 ± 10.25 mmHg. The average systolic blood pressure was slightly above the upper normal limit; however, the average diastolic blood pressure was within normal range. All controls had values of systolic and diastolic blood pressure within normal limits. With the classification of blood pressure in the various degrees of hypertension, it was observed that the largest percentage of diabetic patients had blood pressure situated at the level of grade 1 hypertension (48.2%). The percentage of diabetic patients gradually decreased in higher grades of hypertension (15.5% in grade 2 to 0.9% in grade 3). The proportion of diabetic patients with hypertensive blood pressure values was greater than the proportion of diabetic patients with normal blood pressure values (64.6% versus 35.5%, respectively).

Regarding biochemical parameters, the diabetic group had an average glucose value of 153.72 ± 55.63 mg/dL, an average HbA_{1c} value of $7.11 \pm 1.56\%$, an average HDL cholesterol value of 49.99 ± 12.98 mg/dL, an average total cholesterol value of 180.45 ± 38.55 mg/dL, an average triglycerides value of 153.15 ± 118.49 mg/dL, and an average creatinine value of 1.07 ± 0.42 mg/dL. The average values of glucose and HbA_{1c} were slightly increased, but the other parameters were normal. All controls had normal biochemical parameters.

Regarding harmful habits, 16.4% of diabetic patients had a habit of drinking alcohol, and 7.3% had an active smoking habit. None of the diabetic patients consumed drugs.

The complication with the highest proportion of diabetic patients was cerebrovascular accident (CVA) (12.7%), followed by blindness (4.5%), myocardial infarction and terminal renal failure (1.8% each), and amputation above the ankle (0.9%). The disease most often associated with diabetes was hypertension (76.4%), followed by dyslipidemia (61.8%), neuropathy (49.1%), retinopathy (42.7%), nephropathy (31, 8%), coronary heart disease (14.5%), and heart failure (3.6%).

Comparative Analysis

We conducted a comparative analysis between diabetic patients and controls, of the following parameters: QT and QTc intervals, QT and QTc dispersions, T_{peak}-T_{end} and jT_{peak}-jT_{end} intervals, and T_{peak}-T_{end} and jT_{peak}-jT_{end} dispersions.

QT and QTc intervals

Table 1 shows the comparison of the mean values of the maximum, minimum and mean QT and QTc intervals between

Table 1 – Comparison of mean QT and QTc intervals between diabetics and controls

	Total	Diabetics	Controls	p	
QT interval (ms)	QT _{max}	376.65 \pm 29.54	379.89 \pm 33.07	373.41 \pm 25.26	0.103
	QT _{mean}	365.84 \pm 28.32	366.15 \pm 31.36	365.54 \pm 25.05	0.874
	QT _{min}	355.04 \pm 27.90	352.40 \pm 30.40	357.67 \pm 25.01	0.161
QTc interval (ms)	QTc _{max}	404.51 \pm 24.69	413.70 \pm 28.10	395.31 \pm 16.28	< 0.001
	QT _{mean}	392.86 \pm 22.79	398.74 \pm 26.64	386.97 \pm 16.25	< 0.001
	QTc _{min}	381.21 \pm 22.00	383.78 \pm 26.18	378.63 \pm 16.54	0.083

diabetic patients and controls. The results showed that the mean QT_{max} and QT_{mean} intervals are higher in diabetics when compared with controls, though with no significant differences ($p = 0.103$ and $p = 0.874$ respectively). The average QT_{min} interval was lower in diabetic patients compared with controls, but also with no significant differences ($p = 0.161$). When the QT interval was corrected for heart rate, the mean QTc_{max} , QTc_{mean} and QTc_{min} intervals were higher in diabetics than in controls however, significant differences between diabetic patients and controls were found only in QTc_{max} and QTc_{mean} ($p < 0.001$ for both). In this study, we found only 5.5% of diabetic patients with a prolonged QTc interval; however, none of the controls had a prolonged QTc interval.

Dispersion of QT and QTc

Figure 1 shows the comparison of the mean QT and QTc dispersions between diabetics and controls. The results showed that diabetics have a significantly higher mean QT dispersion than controls (27.49 ± 10.10 versus 15.73 ± 4.18 ms ms, $p < 0.001$). Using the QT dispersion corrected for heart rate, we observed that the differences remained higher in diabetic patients when compared with controls (29.92 ± 10.57 versus

$16.68 \text{ ms} \pm 4.48 \text{ ms}$, $p < 0.001$). A prolonged QT dispersion was found in only 0.9% of diabetics, but we did not find in any of the controls a prolonged QT dispersion. No prolonged QTc dispersion was found in any diabetic patient or control.

$T_{peak}-T_{end}$ and $jT_{peak}-jT_{end}$ intervals

Regarding the comparison of $T_{peak}-T_{end}$ and $jT_{peak}-jT_{end}$ intervals, Table 2 summarizes the results in diabetics and controls. There were no statistically significant differences in any of the comparisons made. Comparing the frequency of subjects with a prolonged Tpeak-Tend interval (above the cut-off limit determined for the study), the results showed that 7.3% of diabetic patients had a prolonged $T_{peak}-T_{end}$ interval, which was not observed in any of the controls. A prolonged $jT_{peak}-jT_{end}$ interval was observed in 6.4% of diabetics, but in no individuals of the control group.

Dispersion of $T_{peak}-T_{end}$ and $jT_{peak}-jT_{end}$

Figure 2 shows the comparison of the mean $T_{peak}-T_{end}$ and $jT_{peak}-jT_{end}$ dispersions between diabetics and controls. The results showed that diabetics had a mean $T_{peak}-T_{end}$ dispersion




Figure 1 – Comparison of mean QT and QTc dispersions between diabetics and controls.

Table 2 – Comparison of $T_{peak}-T_{end}$ and $jT_{peak}-jT_{end}$ intervals between diabetics and controls

	Total	Diabetics	Controls	p	
$T_{peak}-T_{end}$ interval (ms)	D_{II}	68.18 ± 11.33	67.24 ± 13.63	69.12 ± 8.39	0.218
	V_2	70.35 ± 11.84	70.67 ± 14.32	70.03 ± 8.74	0.690
	V_5	66.99 ± 11.91	66.13 ± 14.36	67.84 ± 8.81	0.290
$jT_{peak}-jT_{end}$ interval (ms)	D_{II}	68.95 ± 10.25	68.06 ± 11.81	69.85 ± 8.37	0.195
	V_2	70.52 ± 12.30	71.02 ± 15.05	70.02 ± 8.78	0.240
	V_5	67.30 ± 12.02	66.34 ± 14.32	68.25 ± 9.14	0.550




Figure 2 – Comparison of mean $T_{peak}-T_{end}$ and $jT_{peak}-jT_{end}$ dispersions between diabetics and controls.

significantly higher than controls (13.05 ± 9.36 ms versus 5.07 ± 3.26 , $p < 0.001$). Using the $jT_{peak}-jT_{end}$ dispersion, we observed that differences remained higher in diabetic patients, when compared with controls (12.70 ± 5.13 versus 10.28 ms ± 4.05 ms, $p < 0.001$). In this study, we found only 16.4% of diabetics with a prolonged $T_{peak}-T_{end}$ dispersion, but no control had a prolonged $T_{peak}-T_{end}$ dispersion. A prolonged $jT_{peak}-jT_{end}$ interval dispersion was observed in 12.7% of the diabetics, but it was not observed in any of the controls.

Correlational Analysis

We studied the correlation of gender, age, body mass index, duration of diabetes, systolic and diastolic blood pressure, glucose, HbA_{1c}, total and HDL cholesterol, triglycerides, creatinine, previous cardiovascular events such as stroke, myocardial infarction, stable and unstable angina, with different electrocardiographic parameters. In the bivariate and multivariate analysis, there were no significant correlations between variables.

Discussion and Conclusion

The QT interval is the most used parameter in the electrocardiographic assessment of repolarization and its prolongation is associated with increased risk of arrhythmogenesis. Therefore, in our study, we considered it important to assess this parameter in diabetes, in order to assess the potential risk in these individuals. When comparing the QT interval between diabetics and controls, no significant differences were found; however, the QT interval does not take into account the heart rate and, therefore, these results had no clinical relevance. However, after correcting the QT interval for heart rate using the formula of Bazget, we found significant differences between diabetics and controls, and the QTc_{max} and the QTc_{mean} intervals were significantly higher in diabetics. We found several studies that analyzed the QTc_{max}

interval in diabetics and nondiabetics. Most of these studies obtained results similar to those found in our study. Some studies found a QTc_{max} interval significantly higher in diabetic patients when compared with non-diabetics¹⁶⁻²³. We found only one study that examined the QTc_{mean} interval and had results identical to ours, with a QTc_{mean} interval significantly higher in diabetic patients when compared with controls. In that study no significant differences were found in the QTc_{min} interval, unlike what was observed in our study¹⁷.

The QT dispersion is a parameter that represents the spatial dispersion of repolarization and evaluates the heterogeneities of repolarization, and it is used as an indication of electrical instability and as a marker of arrhythmogenic risk. In our study, when comparing diabetics with controls, we observed significant differences in QT dispersion. The QT dispersion was significantly higher in diabetic patients when compared with controls. When this dispersion was corrected for heart rate, the results were identical, suggesting that the QTc dispersion is a parameter that does not add greater clinical relevance to QT dispersion in the risk stratification of patients with diabetes. The small differences between QT and QTc dispersions are probably due to the inaccuracy of correction values for heart rate, since the greater the QT dispersion, the greater the difference between the two, and vice versa. Several studies have found a significantly greater QT dispersion in diabetics when compared with controls^{16-20,24-25}. Others have found an also significantly higher QTc dispersion in diabetic patients when compared with controls^{16-18,23,25,27,29,30}. However, one study found no significant differences in QT dispersion between diabetics and controls³¹.

The $T_{peak}-T_{end}$ interval is a parameter that reflects the transmural dispersion of repolarization, since its prolongation is associated with an increased arrhythmogenic risk. In this study, the $T_{peak}-T_{end}$ and the $jT_{peak}-jT_{end}$ intervals of diabetics were similar to those measured in controls, with no significant differences. One of the

reasons for these results may have been the use of only three leads (D_{II} , V_2 and V_5), which although providing a substantially orthogonal assessment (XYZ) may not be sufficient to evaluate the transmural dispersion represented by the $T_{peak}-T_{end}$ interval.

The $T_{peak}-T_{end}$ dispersion and the $jT_{peak}-jT_{end}$ dispersion also characterize the regional variation of the transmural dispersion, and their prolongation is also associated with an increased arrhythmogenic risk, so they are used as markers for the risk of arrhythmogenesis. However, we found no study on the dispersion of these intervals in diabetics. Although the mean values were similar in D_{II} , V_2 and V_5 leads, our study showed that diabetics had $T_{peak}-T_{end}$ and $jT_{peak}-jT_{end}$ dispersions significantly higher than the controls.

Gupta et al.³² investigated a new risk marker that was not analyzed in our study, the $T_{peak}-T_{end}/QT$ ratio, which showed increased values in patients with arrhythmic events who had Brugada syndrome, short QT syndrome, and long QT syndrome, and also in patients with organic heart disease, such as myocardial infarction³². A further investigation of the usefulness of this parameter in the identification of diabetics at higher risk of arrhythmogenesis would be an added advantage³³.

These changes in ventricular repolarization in diabetic patients are caused by several clinical disorders and/or pathological conditions associated with diabetes, such as hypertension³⁴, dyslipidemias³⁵, hyperglycemia², hypoglycemia³⁶, coronary disease³⁷, neuropathy¹⁸, nephropathy³⁸, heart failure³⁹, etc. These conditions are responsible for the onset of metabolic disorders, electrolyte disturbances, imbalances of the autonomic nervous system, structural changes, myocardial fibrosis resulting in longer dispersion and/or repolarization time.

Although repolarization parameters were significantly higher in diabetic patients than in controls, the percentage of diabetics with values above normal was relatively small for all parameters. The fact that few diabetics had abnormal values of repolarization parameters indicates that these individuals may have been at relatively low risk of arrhythmia, confirming a good clinical orientation of these patients by the physicians involved. However, it is still important to emphasize that significant differences were observed in a number of parameters evaluated when compared with the control group, indicating that the repolarization in diabetic patients, even if well-controlled in therapeutic terms, was more heterogeneous than that observed in non-diabetic individuals. Moreover, it is worth mentioning that a large proportion of the diabetic patients evaluated had a relatively short duration of illness, and the effects of the disease might not have been sufficiently established to produce greater prolongation of repolarization parameters.

Another fact of great importance is the influence of medication on several electrocardiographic parameters, because there are numerous drugs that cause prolongation and/or dispersion of repolarization. This study excluded individuals receiving medications that are more frequently associated with repolarization changes; however, there was no absolute guarantee that all other medications had no influence on repolarization. In fact, a study by Costa et al.³³ evaluated the influence of metformin (a drug commonly used in diabetics to control blood glucose) on QT interval and QT dispersion in diabetic rats. The results showed that, with low and

moderate doses of metformin, there were significant changes in electrocardiographic parameters, but this did not happen when the dose was high³³. Although no study was conducted in humans, it remains plausible that this result can be identical in diabetic humans, as in diabetic rats. This aspect is particularly relevant in this study since most patients included were treated with metformin.

Furthermore, this study showed a statistically significant difference in BMI between diabetics and controls. However, there were no significant correlations between BMI and repolarization parameters, which led us to conclude that obesity had no significant influence on the various repolarization parameters evaluated. On the other hand, in diabetic patients, systolic blood pressure, diastolic blood pressure, glucose, HbA_{1c}, total cholesterol, HDL cholesterol, triglycerides and creatinine do not appear to significantly influence the repolarization parameters evaluated, since there were no significant correlations between them. These results may not be clinically relevant, since they were obtained from a punctual measurement.

This study was not without limitations. A larger sample would certainly increase the statistical power of the study, and probably some differences would therefore become more expressive. Moreover, manual measurements of intervals without the support of any technology that could ensure a more precise measurement may also be an aspect to be taken into account. The accuracy and reproducibility of measurements of repolarization parameters were limited by difficulties in identifying the end of the T-wave in some cases. One other problem encountered was the lack of a consensus on the values of several normal electrocardiographic parameters. Another drawback was the electrocardiographic recording done in groups of 3 simultaneous leads, since a record of 12 simultaneous leads would allow a more accurate measurement of several repolarization parameters in the same cardiac cycle.

Despite some methodological limitations, this study clearly demonstrated a relationship between diabetes and changes in a set of electrophysiological parameters that indicate a prolonged and more heterogeneous repolarization in these patients, when compared with healthy subjects. This fact may be involved in the greater vulnerability of these patients to cardiac arrhythmias. Therefore, the assessment of these new markers for arrhythmogenic risk may be important for better risk stratification of diabetic patients, a conclusion that needs confirmation in larger prospective studies.

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Sources of Funding

There were no external funding sources for this study.

Study Association

This article is part of the master thesis submitted by David da Silva Clemente, from Escola Superior de Tecnologia da Saúde de Coimbra.

References

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract.* 2010;87(1):4-14.
2. Kumar R, Fisher M, Macfarlane PW. Diabetes and QT interval: time for debate. *Br J Diabetes Vasc Dis.* 2004;4:146-9.
3. Okin PM, Devereux -RB, Howard BV, Fabsitz RR, Lee ET, Welty TK. Assessment of QT interval and QT dispersion for prediction of all-cause and cardiovascular mortality in American Indians: The Strong Heart Study. *Circulation.* 2000;101(1):61-6.
4. Cardoso CR, Salles GF, Deccache W. Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. *J Diabetes Complications.* 2003 ;17(4):169-78.
5. Veglio M, Chinaglia A, Cavallo-Perin P. QT interval, cardiovascular risk factors and risk of death in diabetes. *J Endocrinol Invest.* 2004;27(2):175-81.
6. Sá R, Perez C. Dispersão de QT: o seu significado clínico. *Rev SOCERJ.* 2004;17(3):183-91.
7. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. *Eur Heart J.* 2000;21(15):1216-31.
8. Corrado D, Pelliccia A, Bjornstad HH, Vanhees L, Biffi A, Borjesson M, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. *Eur Heart J.* 2005;26(5):516-24.
9. Surawicz B. Will QT dispersion play a role in clinical decision-making? *J Cardiovasc Electrophysiol.* 1996;7(8):777-84.
10. Salles GF, Deccache W, Cardoso CR. Usefulness of QT-interval parameters for cardiovascular risk stratification in type 2 diabetic patients with arterial hypertension. *J Hum Hypertens.* 2005;19(3):241-9.
11. Castro Hevia J, Antzelevitch C, Tornes Barzaga F, Dorantes Sanchez M, Dorticos Balea F, Zayas Molina R, et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. *J Am Coll Cardiol.* 2006;47(9):1828-34.
12. Mozos I, Serban C. The relation between QT interval and T-wave variables in hypertensive patients. *J Pharm Bioallied Sci.* 2011;3(3):339-44.
13. James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. *Obes Res.* 2001;9 (Suppl 4):228S-33S.
14. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. *J Hypertens.* 2007;25(9):1751-62.
15. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. *N Engl J Med.* 2004;351(15):1548-63.
16. Yoon JS, Won KC, Lee HW. The relation of QTc dispersion and cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus. *J Korean Diabetes Assoc.* 1998;22(3):410-18.
17. Kumhar MR, Agarwal TD, Singh VB, Kochar DK, Chadda VS. Cardiac autonomic neuropathy and its correlation with QTc dispersion in type 2 diabetes. *Indian Heart J.* 2000;52(4):421-6.
18. Familoni OB, Odusan O, Raimi TH. The relationship between QT intervals and cardiac autonomic neuropathy in nigerian patients with type 2 diabetes mellitus. *Niger Med Pract.* 2008;53(3):48-51.
19. Arildsen H, May O, Christiansen EH, Damsgaard EM. Increased QT dispersion in patients with insulin-dependent diabetes mellitus. *Int J Cardiol.* 1999;71(3):235-42.
20. Langen KJ, Ziegler D, Weise F, Piolot R, Boy C, Hubinger A, et al. Evaluation of QT interval length, QT dispersion and myocardial m-iodobenzylguanidine uptake in insulin-dependent diabetic patients with and without autonomic neuropathy. *Clin Sci (Lond).* 1997;93(4):325-33.
21. Takebayashi K, Aso Y, Sugita R, Takemura Y, Inukai T. Clinical usefulness of corrected QT intervals in diabetic autonomic neuropathy in patients with type 2 diabetes. *Diabetes Metab.* 2002;28(2):127-32.
22. Jermendy G, Koltai MZ, Pogatsa G. QT interval prolongation in type 2 (non-insulin-dependent) diabetic patients with cardiac autonomic neuropathy. *Acta Diabetol Lat.* 1990;27(4):295-301.
23. Sakabe K, Fukuda N, Fukuda Y, Wakayama K, Nada T, Morishita S, et al. QT-interval dispersion in type 2 diabetic and non-diabetic patients with post-myocardial infarction. *Nutr Metab Cardiovasc Dis.* 2008;18(2):121-6.
24. Takebayashi K, Sugita R, Tayama K, Aso Y, Takemura Y, Inukai T. The connection between QT dispersion and autonomic neuropathy in patients with type 2 diabetes. *Exp Clin Endocrinol Diabetes.* 2003;111(6):351-7.
25. Aytemir K, Aksoyok S, Ozer N, Gurlek A, Oto A. QT dispersion and autonomic nervous system function in patients with type 1 diabetes. *Int J Cardiol.* 1998;65(1):45-50.
26. Galetta F, Franzoni F, Prattichizzo F, Tintori G, Cinotti F, Taccola D, et al. [QT dispersion in insulin-dependent diabetics]. *G Ital Cardiol.* 1999 Jun;29(6):675-8.
27. Cardoso C, Salles G, Bloch K, Deccache W, Siqueira-Filho AG. Clinical determinants of increased QT dispersion in patients with diabetes mellitus. *Int J Cardiol.* 2001;79(2-3):253-62.
28. Deyneli O, Ersoz HO, Yavuz D, Fak AS, Akalin S. QT dispersion in type 2 diabetic patients with altered diurnal blood pressure rhythm. *Diabetes Obes Metab.* 2005 ;7(2):136-43.
29. Lengyel C, Varkonyi T, Boda K, Fazekas T. [Increase of the QT interval dispersion in diabetes mellitus]. *Orv Hetil.* 1997;138(6):337-41.
30. Wei K, Dorian P, Newman D, Langer A. Association between QT dispersion and autonomic dysfunction in patients with diabetes mellitus. *J Am Coll Cardiol.* 1995;26(4):859-63.
31. Psallas M, Tentolouris N, Papadogiannis D, Doulgerakis D, Kokkinos A, Cokkinos DV, et al. QT dispersion: comparison between participants with Type 1 and 2 diabetes and association with microalbuminuria in diabetes. *J Diabetes Complications.* 2006;20(2):88-97.
32. Gupta P, Patel C, Patel H, Narayanaswamy S, Malhotra B, Green JT, et al. T(p-e)/QT ratio as an index of arrhythmogenesis. *J Electrocardiol.* 2008;41(6):567-74.
33. Costa EC, Goncalves AA, Areas MA, Morgabel RG. Effects of metformin on QT and QTc interval dispersion of diabetic rats. *Arq Bras Cardiol.* 2008;90(4):232-8.
34. Vilas-Boas F, Castro Lima A, Torreão J, Feitosa GS. Dispersão Temporal do QT em Pacientes com Hipertensão Arterial Sistêmica. *Arq Bras Cardiol.* 1997;68(5):343-6.
35. Faramawi MF, Wildman RP, Gustaf J, Rice J, Abdul Kareem MY. The association of the metabolic syndrome with QTc interval in NHANES III. *Eur J Epidemiol.* 2008;23(7):459-65.
36. Robinson RT, Harris ND, Ireland RH, Lee S, Newman C, Heller SR. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. *Diabetes.* 2003;52(6):1469-74.

-
37. Veglio M, Giunti S, Stevens LK, Fuller JH, Perin PC. Prevalence of Q-T interval dispersion in type 1 diabetes and its relation with cardiac ischemia: the EURODIAB IDDM Complications Study Group. *Diabetes Care*. 2002;25(4):702-7.
 38. Sawicki PT. Mortality in diabetic nephropathy: the importance of the QT interval. *Nephrol Dial Transplant*. 1996;11(8):1514-5.
 39. Szejf C, Rays J, Gebara OC, Vieira NW, Pierri H, Nussbacher A, et al. Relação entre os Comportamentos das Dispersões da Onda P e do Intervalo QT em Idosos com Insuficiência Cardíaca. *Arq Bras Cardiol*. 2002;79:494-6.